Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF)
Public ClinicalTrials.gov record NCT02072434. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Prospective, Randomized, Open-Label Blinded Endpoint Evaluation (PROBE) Parallel Group Study Comparing Edoxaban (DU-176b) With Enoxaparin/Warfarin Followed by Warfarin Alone in Subjects Undergoing Planned Electrical Cardioversion of Nonvalvular Atrial Fibrillation
Study identification
- NCT ID
- NCT02072434
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Daiichi Sankyo
- Industry
- Enrollment
- 2,199 participants
Conditions and interventions
Conditions
Interventions
- Edoxaban Drug
- Enoxaparin Drug
- Warfarin Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 24, 2014
- Primary completion
- Feb 2, 2016
- Completion
- Feb 2, 2016
- Last update posted
- Mar 14, 2019
2014 – 2016
United States locations
- U.S. sites
- 28
- U.S. states
- 13
- U.S. cities
- 28
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Phoenix | Arizona | — | — |
| Not listed | Escondido | California | — | — |
| Not listed | Newport Beach | California | — | — |
| Not listed | Riverside | California | — | — |
| Not listed | San Francisco | California | — | — |
| Not listed | Santa Rosa | California | — | — |
| Not listed | Denver | Colorado | — | — |
| Not listed | Stamford | Connecticut | — | — |
| Not listed | Newark | Delaware | — | — |
| Not listed | Clearwater | Florida | — | — |
| Not listed | Daytona Beach | Florida | — | — |
| Not listed | Jupiter | Florida | — | — |
| Not listed | Rockledge | Florida | — | — |
| Not listed | Sarasota | Florida | — | — |
| Not listed | Tampa | Florida | — | — |
| Not listed | Boise | Idaho | — | — |
| Not listed | Auburn | Maine | — | — |
| Not listed | Rochester | Minnesota | — | — |
| Not listed | Allentown | Pennsylvania | — | — |
| Not listed | Butler | Pennsylvania | — | — |
| Not listed | Camp Hill | Pennsylvania | — | — |
| Not listed | Hershey | Pennsylvania | — | — |
| Not listed | Jackson | Tennessee | — | — |
| Not listed | Dallas | Texas | — | — |
| Not listed | Fort Worth | Texas | — | — |
| Not listed | Plano | Texas | — | — |
| Not listed | Tyler | Texas | — | — |
| Not listed | Richmond | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 200 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02072434, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 14, 2019 · Synced May 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02072434 live on ClinicalTrials.gov.